Shockwave Medical
Shockwave Medical [SWAV] created a highly innovative technology focused on solving the problem of heavily calcified arteries, for patients with Peripheral and Coronary Artery Disease (PAD and CAD). The therapy also has promising applications in aortic valve stenosis.
Sector
Medical Devices
Strategy
Capital
Status
Exit
Website
shockwavemedical.com
Related News
Johnson & Johnson to acquire Shockwave Medical
Shockwave Medical announces agreement to acquire Neovasc
Shockwave Appoints Maria Sainz to Board of Directors
Shockwave Announces Pricing of Public Offering of Common Stock
Shockwave Medical Announces That CMS Has Created New Codes for Intravascular Lithotripsy
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.